Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
162 hedge funds and large institutions have $2.57B invested in Spark Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 50 increasing their positions, 50 reducing their positions, and 27 closing their positions.
34% more capital invested
Capital invested by funds: $1.92B → $2.57B (+$649M)
30% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 27
1% more funds holding
Funds holding: 160 → 162 (+2)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 50
13% less call options, than puts
Call options by funds: $21.8M | Put options by funds: $25.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$38.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$36.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.8M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$15.5M |
| 5 |
PC
PointState Capital
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$25.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$20.4M |
| 3 |
Goldman Sachs
New York
|
-$13.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.5M |
| 5 |
IPLA
Ice Pond Lane Advisers
New York
|
-$10.9M |
ONCE Hedge Fund Activity: Q1 2018 in Review
162 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q1 2018, worth a combined $2.57B — up 34% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ONCE positions and 27 closed out — a net gain of 8 holders — while 50 added to existing stakes and 50 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $38.3M. The largest seller was Janus Henderson Group, cutting an estimated $25.5M.
- 162 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q1 2018, up from 160 in Q4 2017.
- Funds reported $2.57B of Spark Therapeutics, Inc. Common Stock stock for Q1 2018, up 34% quarter-over-quarter.
- 35 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q1 2018 and 27 closed out, a net change of +8 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q1 2018 was Wellington Management Group, an estimated $38.3M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q1 2018 was Janus Henderson Group, an estimated $25.5M sold.
Based on aggregated 13F filings for Q1 2018.